Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared on X:
“MARIPOSA Johnson and Johnson announces Positive OS results in 1L EGFR
Amivantamab + lazertinib vs. osimertinib:
Statistically significant improvement in OS (press release states >1 yr survival benefit)
Await complete data and presentation.”
